{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:14:08Z","timestamp":1789071248773,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Thymus and activation-regulated chemokine (TARC; CCL17) is a T-helper-2 chemokine that reflects atopic dermatitis (AD) disease activity. Since 2008, serum TARC levels have been commercially measured in Japan, and clinical experience has shown the usefulness of TARC. The fallacy that eczema is always visible often hinders successful treatment, when there is subclinical inflammation which is inferable from the TARC level. AD treatment has entered a new era with higher therapeutic efficacy. TARC has a different meaning than it did previously, and its significance and limitations are discussed. First, a more appropriate topical therapy monitoring TARC would be useful in selecting truly necessitated patients for expensive new therapies. Dupilumab quickly lowers serum TARC before clinical improvement, and its normalization is not a criterion for dose reduction. However, in some severe cases, TARC may help determine whether to continue treatment. During treatment with JAK inhibitors, serum TARC levels are often elevated and may be abnormally high, leading to the exacerbation of dermatitis. Prurigo nodularis is divided into two types associated with elevated and normal TARC levels, which may aid in the selection of therapeutic agents. In this new era, TARC remains a useful biomarker for more accurate drug selection and the determination of therapeutic efficacy; Currently, in clinical trials of AD, all outcome measurements depend on the clinical score; however the use of a biomarker, such as TARC, as a secondary outcome measure will clarify the characteristics of each drug and the pathophysiological conditions for which it is expected to be effective.<\/jats:p>","DOI":"10.3389\/falgy.2024.1473902","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:00:08Z","timestamp":1737615608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era"],"prefix":"10.3389","volume":"5","author":[{"given":"Yoko","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105121","DOI":"10.1016\/j.ebiom.2024.105121","article-title":"Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review","volume":"103","author":"Park","year":"2024","journal-title":"eBioMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the international eczema council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1046\/j.1523-1747.2000.00115.x","article-title":"A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin","volume":"115","author":"Vestergaard","year":"2000","journal-title":"J Investig Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Aallergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1111\/1346-8138.15036","article-title":"Reduction of serum thymus and activation-regulated chemokine after short-term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis","volume":"46","author":"Saito","year":"2019","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.12932\/AP0419.32.3.2014","article-title":"Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments","volume":"32","author":"Yasukochi","year":"2013","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jaci.2013.12.1079","article-title":"Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?","volume":"133","author":"Tang","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1111\/1346-8138.16527","article-title":"English version of clinical practice guidelines for the management of atopic dermatitis 2021","volume":"49","author":"Saeki","year":"2022","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.14924\/dermatol.110.1099","article-title":"Committee for guidelines for therapy for atopic dermatitis of Japanese dermatological association. Guidelines for therapy for atopic dermatitis","volume":"110","author":"Kawashima","year":"2000","journal-title":"Jpn J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/bjd\/ljad498.006","article-title":"495 - lebrikizumab reduces systemic inflammation in the serum of patients with moderate-to-severe atopic dermatitis","volume":"190","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/bjd\/ljad159","article-title":"Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry","volume":"189","author":"Spekhorst","year":"2023","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad162.034","article-title":"Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis","volume":"188","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1365544","DOI":"10.3389\/fimmu.2024.1365544","article-title":"Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks","volume":"15","author":"Hagino","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/cea.14442","article-title":"Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation","volume":"54","author":"Boesjes","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the international eczema council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e072350","DOI":"10.1136\/bmjopen-2023-072350","article-title":"Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol","volume":"13","author":"Mar\u00edn-Cand\u00f3n","year":"2023","journal-title":"BMJ Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.anai.2023.12.022","article-title":"Topical steroid withdrawal and atopic dermatitis","volume":"132","author":"Marshall","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ced\/llad161","article-title":"Topical steroid withdrawal: an emerging clinical problem","volume":"48","author":"Brookes","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","article-title":"Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomised, double-blind, placebo-controlled, phase II\/III clinical study in patients aged \u226513 years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","article-title":"Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis","volume":"152","author":"Alkon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.15107","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1084\/jem.20061791","article-title":"IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung","volume":"204","author":"Perrigoue","year":"2007","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1111\/bjd.16543","article-title":"Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative)","volume":"178","author":"Chalmers","year":"2018","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10067-020-05001-x","article-title":"Treatment strategies are more important than drugs in the management of rheumatoid arthritis","volume":"39","author":"Drosos","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","article-title":"Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies","volume":"101","author":"Bruin-Weller","year":"2021","journal-title":"Acta Derm-Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.2340\/actadv.v103.5382","article-title":"The treat-to-target project in atopic dermatitis: one year on","volume":"103","author":"Bruin-Weller","year":"2023","journal-title":"Acta Derm-Venereol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/imcb.12644","article-title":"CCL17\/TARC in autoimmunity and inflammation-not just a T-cell chemokine","volume":"101","author":"Lupancu","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","article-title":"Identification of thymus and activation-regulated chemokine (TARC\/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)\/drug rash with eosinophilia and systemic symptoms (DRESS)","volume":"69","author":"Ogawa","year":"2013","journal-title":"J Dermatol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.2023020959","article-title":"Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years","volume":"142","author":"Diepstra","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1473902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:00:11Z","timestamp":1737615611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1473902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":43,"alternative-id":["10.3389\/falgy.2024.1473902"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1473902","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1473902"}}